Taicang Connect Bio reported that its interleukin-4 receptor alpha (IL-4Rα) candidate met its primary endpoint in a global Phase II trial for atopic dermatitis. The trial tested CBP-201 in three dosing arms, all of which showed statistically significant improvements of 50% to 75% eczema reduction compared to currently available therapies. Although the news was positive, Connect's stock price dropped 50% to $5.75. The company's stock price has now dropped 66% from the level of its March IPO, which was priced at $17 per share. More details.... Stock Symbol: (NSDQ: CNTB) Share this with colleagues: // //